A PET study of 148 PSP patients using [18F]florzolotau (a.k.a. [18F]PM-PBB3 or [18F]APN-1607, Fig. 1C) has shown promise to detect tau accumulation typical of PSP pathophysiology; however, longitudinal follow-up studies are necessary to determine whether [18F]florzolotau can be a reliable diagnostic tool for PSP27. Here, MAPT is linked to supranuclear palsy, progressive, 1.